Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRDL | US
-0.03
-2.92%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
06/03/2026
0.97
1.00
1.00
0.97
Cardiol Therapeutics Inc. a clinical-stage life sciences company focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx which is in Phase II/III multi-national randomized double-blind and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19 as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville Canada.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
40.5%1 month
46.0%3 months
51.6%6 months
53.8%-
-
13.69
0.01
0.01
0.30
178.81
-
-31.66M
77.29M
77.29M
-
-
-
-
-108.44
1.79
1.06
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.10
Range1M
0.15
Range3M
0.19
Rel. volume
1.72
Price X volume
564.53K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cannex Capital Holdings Inc | ARRXF | Drug Manufacturers-Specialty & Generic | 0.2542 | 64.78M | 5.92% | n/a | 0.50% |
| Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 2.72 | 64.32M | 0.74% | n/a | 24.34% |
| Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 3.5 | 49.33M | -0.57% | n/a | 81.86% |
| Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 8.13 | 43.48M | -0.73% | n/a | 0.00% |
| INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 0.8202 | 37.54M | -3.55% | n/a | 28.90% |
| SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 0.8 | 30.29M | 0.95% | n/a | 25.73% |
| Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.0523 | 21.96M | 0.00% | n/a | 0.00% |
| India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.2859 | 21.62M | -1.41% | n/a | 4.33% |
| China SXT Pharmaceuticals Inc | SXTC | Drug Manufacturers-Specialty & Generic | 2.04 | 7.09M | 0.00% | n/a | 19.00% |
| PRFX | PRFX | Drug Manufacturers-Specialty & Generic | 2.62 | 5.83M | -4.73% | n/a | -2.89% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Unifi Inc | UFI | Textile Manufacturing | 3.97 | 72.47M | 2.06% | n/a | 52.56% |
| ILAG | ILAG | Building Products & Equipment | 2.4783 | 44.76M | 6.82% | n/a | 5.48% |
| Culp Inc | CULP | Textile Manufacturing | 3.24 | 40.47M | 0.00% | n/a | 11.29% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.21 | 32.29M | -3.49% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6345 | 12.26M | -10.63% | n/a | 58.43% |
| The Dixie Group Inc | DXYN | Textile Manufacturing | 0.4634 | 7.13M | 3.90% | n/a | 422.08% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.4799 | 3.78M | -0.68% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.397 | 3.78M | -1.73% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.39 | 1.32M | -3.24% | n/a | 0.00% |
| Blackstone/GSO Senior Floating Rate Term Fund | BSL | Textile Manufacturing | 12.69 | 0 | -0.86% | n/a |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.30 | 24.85 | Cheaper |
| Ent. to Revenue | 178.81 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 13.69 | 13.15 | Par |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 51.56 | 65.24 | Lower Risk |
| Debt to Equity | 0.01 | -1.88 | Expensive |
| Debt to Assets | 0.01 | 0.48 | Cheaper |
| Market Cap | 77.29M | 3.71B | Emerging |